4Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a muhidrug regimen in the developing world: a cost-effectiveness analysis[J]. Lancet, 2006,19,368(9536) :679
5Lanza CA, Fox K, Crea F. Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing[ J ]. Adv Cardiol,2006,43:1
6Siddiqui A, Kowey PR. Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies[ J]. Curr Opin Cardiol,2006,21(5) :517
7Viitasalo M, Oikarinen L, Swan H, et al. Effects of beta-blocker therapy on ventricular repolarization documented by 24 h electrocardiography in patients with type 1 long-QT syndrome[J]. J Am Coll Cardiol,2006,48 (4) :747
8Pedersen ME, Cockcroft JR. The latest generation of beta-blockers :new pharmacologic properties [ J ]. Curr Hypertens Rep, 2006, 8(4):279
9Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines[J]. Eur Heart J, 2006,27(16) :1 979
10Zipes DP, Carom AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sadden cardiac death-executive summary : a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines [ J ]. Eur Heart J, 2006,27 ( 17 ) :2 099
